Grant: Canada Research Chairs
University of Victoria
$100,000.00
Bioactive Small Molecule Synthesis
EF 2018-19
Résumé
New opportunities in personalized medicine have created a need for larger numbers of selective drug molecules. To address this need, Dr. Wulff has worked to invent efficient synthetic methods that can be used to access a suite of conformationally constrained scaffold molecules. In the second term of his CRC, he proposes to apply these scaffolds to create new drug candidates that potently and selectively bind to medicinally important protein targets. These new agents will ultimately be used for the treatment of several types of human cancer.
Programme
Canada Research Chairs
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
1000231376-2016
Name nom
Wulff, Jeremy
Department département
Chemistry / Science / Victoria
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2016
Award amount
100000
Program id
CRC
Program name en
Canada Research Chairs
Program name fr
Chaires de recherche du Canada
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
9998
Committee name en
Canada Research Chair Selection Committee
Committee name fr
Comité de sélection des Chaires de recherche du Canada
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
0
Nb partie
NA
Application title
Bioactive Small Molecule Synthesis
Keyword
NSERC
Application summary
New opportunities in personalized medicine have created a need for larger numbers of selective drug molecules. To address this need, Dr. Wulff has worked to invent efficient synthetic methods that can be used to access a suite of conformationally constrained scaffold molecules. In the second term of his CRC, he proposes to apply these scaffolds to create new drug candidates that potently and selectively bind to medicinally important protein targets. These new agents will ultimately be used for the treatment of several types of human cancer.